Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

1. (Currently Amended) An immediate release pharmaceutical formulation comprising, as an active ingredient, a compound of formula (I) :



(I)

wherein

R^1 ~~represents~~ is C_{1-2} alkyl substituted ~~by~~ with one or more fluoro substituents;

R^2 ~~represents~~ is hydrogen, hydroxy, methoxy or ethoxy; and

n ~~represents~~ is 0, 1 or 2;

or a pharmaceutically acceptable salt thereof; and

a pharmaceutically acceptable diluent or carrier; provided that when the active ingredient is other than in the form of a salt, the formulation does not solely contain:

- a solution of one active ingredient and water;
- a solution of one active ingredient and dimethylsulphoxide; or
- a solution of one active ingredient in a mixture of ethanol:PEG 660 12-hydroxy stearate:water 5:5:90.

2. (Currently Amended) An immediate release pharmaceutical formulation as claimed in claim 1, comprising an acid addition salt of a compound of formula (I) and a pharmaceutically acceptable diluent or carrier.

3. (Currently Amended) An immediate release pharmaceutical formulation as claimed in claim 1, ~~or 2~~ wherein the active ingredient is:
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe);
Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab;
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OH);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OH);
Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab; or
Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OH).

4. (Currently Amended) A formulation as claimed in claim 1, ~~2 or 3~~ wherein the active ingredient is a crystalline salt of:
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe);
Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe); or
Ph(3-Cl)(5-OCH_2CH_2F)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe).

5. (Currently Amended) A formulation as claimed in ~~any one of claims~~claim 1, ~~to 4~~ wherein the active ingredient is an ethanesulfonic acid, *n*-propanesulfonic acid, benzenesulfonic acid, 1,5-naphthalenedisulfonic acid, or n-butanesulfonic acid addition salt of Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe) or Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe).

6. (Currently Amended) A formulation as claimed in ~~any one of claims~~claim 1, ~~to 5~~ wherein the active ingredient is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(OMe), benzene-sulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 5.9, 4.73, 4.09, and 4.08Å.

7. (Currently Amended) A formulation as claimed in ~~any one of claims~~claim 1, ~~to 5~~ wherein the active ingredient is Ph(3-Cl)(5-$OCHF_2$)-(*R*)CH(OH)C(O)-(*S*)Aze-Pab(2,6-diF)(OMe), hemi-1,5-naphthalenedisulfonic acid salt, characterised by an X-ray powder diffraction pattern characterised by peaks with d-values at 18.3, 9.1, 5.6, 5.5, 4.13, 4.02, 3.86, 3.69, and 3.63Å.

8. (Currently Amended) A formulation as claimed in ~~any one of claims~~claim 1, ~~to 7~~ wherein the composition is selected from a solid immediate release pharmaceutical formulation, an injectable immediate release pharmaceutical formulation, or a liquid immediate release oral pharmaceutical formulation.

9. (Currently Amended) A method ~~of~~ for treating a patient suffering from, or at risk of developing a cardiovascular disorder, ~~in a patient suffering from, or at risk of, said disorder, which comprises~~comprising administering to the patient a therapeutically effective amount of a pharmaceutical formulation of any one of claims 1 to 8.